CaridianBCT, Inc. (CaridianBCT), is planning to complete the phase I trial entitled "IMPROVE: Inactivation of Whole Blood With Mirasol: Performance in Red Blood Cells, Platelets and Plasma Investigation" for Mirasol Pathogen Reduction Technology System by December 2009. The purpose of the feasibility trial to determine recovery and survival of RBCs from Mirasol-treated whole blood. The study is currently recruiting participants in US.
This non-randomized, single blind (subject), parallel assignment study will enroll 18 patients. The study Principal Investigator is Jose A Cancelas-Perez, MD from University of Cincinnati, Hoxworth Blood Center.
The Mirasol Pathogen Reduction Technology System enhances the safety of the blood supply during blood transfusion. It reduces the active pathogen load and inactivates residual white blood cells present in donated blood components. It alters the nucleic acids of disease-causing agents in blood products using riboflavin and UV light.
CaridianBCT is a provider of automated blood collections, therapeutic apheresis and cell therapy systems, whole blood processes and pathogen reduction technologies.